Patent intelligence · US
US 7585852
Cobalamine derivatives useful for diagnosis and treatment of abnormal cellular proliferation
Cobalamine derivatives useful for diagnosis and treatment of abnormal cellular proliferation
Patent details — US 7585852
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 8, 2009
- Expiration
- Sep 3, 2029
- Applicant
- Solidago AG
- Claims
- 17
- CPC classes
- A61K, A61K51/041, A61K51/0482, A61K51/0497
Quick answer
US 7585852 (Cobalamine derivatives useful for diagnosis and treatment of abnormal cellular proliferation) is held by Solidago AG. Status: granted. Granted Sep 8, 2009. Expires Sep 3, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Solidago AG
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K51/041, A61K51/0482, A61K51/0497, A61P, A61P31/00
More from Solidago AG
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 7585852?
US 7585852 (Cobalamine derivatives useful for diagnosis and treatment of abnormal cellular proliferation) is held by Solidago AG. Status: granted. Granted Sep 8, 2009. Expires Sep 3, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7585852?
Solidago AG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 7585852 expire?
Our index shows an expiration date of Sep 3, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.